DLL3 and neoplasm: Emerging therapies targeting DLL3, such as bispecific T-cell engager (BiTE) and chimeric antigen receptor (CAR) T cells, show promising anti-tumor activity in clinical trials and synergize with immune checkpoint inhibitors.